Significant improvement of portopulmonary hypertension after 1-week terlipressin treatment.
Cirrhosis associated with moderate and severe portopulmonary hypertension carries a poor prognosis. Optimal management has not yet been defined. Current treatment options, such as prostacyclin analogues, endothelin antagonists, and phosphodiesterase-5 inhibitors, are characterized by slow onset of action and various adverse effects, particularly in patients with advanced cirrhosis. Here, we report the significant reduction of pulmonary arterial pressure after 1-week terlipressin treatment in a patient with concomitant hepato-renal syndrome. Terlipressin could be a novel and safe treatment for portopulmonary hypertension.
Kalambokis
Georgios
G
1st Division of Internal Medicine, University of Ioannina, Medical School, 45110 Ioannina, Greece.
Korantzopoulos
Panagiotis
P
Nikas
Spyros A
SA
Theodorou
Areti
A
Tsianos
Epameinondas V
EV
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications / Q000188:drug therapy*; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D007275:Injections, Intravenous; D008236:Lypressin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D012772:Shock, Septic; D000077585:Terlipressin; D013997:Time Factors
D000959:Antihypertensive Agents; D008236:Lypressin; D000077585:Terlipressin